EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
432
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of a Securities Action on Behalf of Shareholders of J.Jill, Inc. and a Lead Plaintiff Deadline of December 12, 2017 – JILL

NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common stock of J.Jill, Inc. (“J.Jill”) (NYSE: JILL ) pursuant and/or traceable to the Company’s Initial Public Offering on or around October 9, 2017 . To get more information go to:

http://www.zlkdocs.com/JILL-Info-Request-Form-6149

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that the Registration Statement and Prospectus filed for the Company’s IPO contained materially false and misleading statements and/or failed to disclose that: (1) the Company’s purportedly unique and superior sales and marketing approach had not insulated the Company from adverse trends affecting the overall retail industry; (2) the Company’s historic gross margin growth was not sustainable and would not continue, as it relied on various short-term boosts to revenues; (3) the Company was carrying increasing amounts of slow moving inventory and would need to significantly markdown sales items and increase promotional efforts in an attempt to continue its sales growth; (4) the Company’s brick-and-mortar stores were failing, as they were experiencing difficulty attracting customers and maintaining profitability, which would result in the Company shuttering up to eight stores in fiscal 2017, with the rate of store closures accelerating; and (5) as a result of the aforementioned, J.Jill’s business, prospects and ability to service its long-term debt had been materially impaired.

If you suffered a loss in J.Jill you have until December 12, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004            Tel: (212) 363-7500 Toll Free:  (877) 363-5972 Fax: (212) 363-7171 www.zlk.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Important Legal Opportunity for Coinbase Investors in Class Action

Updated Category News Views 114

Key Opportunity for Coinbase Investors Investors holding Coinbase Global, Inc. (NASDAQ: COIN) securities may have a significant opportunity to participate in a class action lawsuit alleging serious violations of securities regulations. This opportunity arises from actions that took place during the specified Class Period. Investors are encouraged to evaluate their...

Continue Reading
BridGene Biosciences Secures $28 Million for Drug Development

Updated Category News Views 244

BridGene Biosciences Raises Significant Funding BridGene Biosciences, Inc., renowned for its innovative approach in developing small molecule drugs, recently announced the completion of a substantial $28 million Series B+ financing round. This funding round was spearheaded by Bayland Capital, alongside notable contributions from GTJA Investment Group, Proxima Ventures,...

Continue Reading
NMD Pharma Breaks Ground with NMD670 in Rare Neuromuscular Treatment

Updated Category News Views 177

NMD Pharma's Innovative Phase 2 Study with NMD670 NMD Pharma A/S, an ambitious clinical-stage biotech company, is making strides in the fight against neuromuscular diseases. They have officially begun their Phase 2a clinical trial of NMD670, a novel treatment aimed at addressing the challenges faced by patients with Charcot-Marie-Tooth (CMT) disease types 1 and 2. This...

Continue Reading
Becker Milk Company Limited Announces Half-Year Financial Overview

Updated Category News Views 89

Introduction to Becker Milk Company's Financial Landscape Becker Milk Company Limited is making headlines with its financial results for the first half of its fiscal year. The latest report showcases their performance, reflecting on revenues and net income trends. Financial Highlights Overview Total revenues for the first six months reveal a detail-oriented insight into...

Continue Reading
Mini Melts Collaborates with 7-Eleven for Blue Raspberry Flavor

Updated Category News Views 354

Exciting New Flavor Launch from Mini Melts and 7-Eleven In an exciting collaboration, Mini Melts USA, a leader in premium beaded ice cream, has partnered with 7-Eleven, Inc. to introduce a new flavor reminiscent of the classic Blue Raspberry Slurpee. This innovative flavor captures the essence of the much-loved frozen drink, providing fans with a delightful and nostalgic...

Continue Reading